BRPI0415639A - formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia - Google Patents

formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia

Info

Publication number
BRPI0415639A
BRPI0415639A BRPI0415639-0A BRPI0415639A BRPI0415639A BR PI0415639 A BRPI0415639 A BR PI0415639A BR PI0415639 A BRPI0415639 A BR PI0415639A BR PI0415639 A BRPI0415639 A BR PI0415639A
Authority
BR
Brazil
Prior art keywords
profiles
dosage forms
controlled release
oral dosage
once daily
Prior art date
Application number
BRPI0415639-0A
Other languages
English (en)
Inventor
Stephen Hwang
Padmaja Shivanand
Nisht B Modi
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of BRPI0415639A publication Critical patent/BRPI0415639A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

"FORMAS DE DOSAGEM DE OXICODONA DE LIBERAçãO CONTROLADA, ORAL, UMA VEZ POR DIA". Formulações de oxicodona são fornecidas as quais produzem perfis de plasma em estado constante em vivo substancialmente fixos. Níveis de tolerância associados com tais perfis e níveis de tolerância associados com perfis bifásicos não são mostrados serem estatisticamente diferentes. Os perfis de plasma em estado constante em vivo substancialmente fixos são produzidos por formas de dosagem que têm perfis de liberação de ordem substancialmente zero. Tais perfis de liberação produzem níveis de C~ max~ em vivo de dose única baixa que podem reduzir a probabilidade de efeitos colaterais adversos.
BRPI0415639-0A 2003-10-29 2004-10-28 formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia BRPI0415639A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51588003P 2003-10-29 2003-10-29
PCT/US2004/036132 WO2005041968A2 (en) 2003-10-29 2004-10-28 Once-a-day, oral, controlled-release, oxycodone dosage forms

Publications (1)

Publication Number Publication Date
BRPI0415639A true BRPI0415639A (pt) 2006-12-12

Family

ID=34549453

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415639-0A BRPI0415639A (pt) 2003-10-29 2004-10-28 formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia

Country Status (14)

Country Link
EP (1) EP1677798A2 (pt)
JP (1) JP2007509979A (pt)
KR (1) KR20060108690A (pt)
CN (1) CN1933837A (pt)
AU (1) AU2004285547A1 (pt)
BR (1) BRPI0415639A (pt)
CA (1) CA2546691A1 (pt)
EC (1) ECSP066534A (pt)
IL (1) IL175193A0 (pt)
MA (1) MA28215A1 (pt)
NO (1) NO20062398L (pt)
RU (1) RU2006118323A (pt)
WO (1) WO2005041968A2 (pt)
ZA (1) ZA200604310B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
AU2002227383B2 (en) 2000-10-30 2004-07-08 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
TWI454288B (zh) 2008-01-25 2014-10-01 Gruenenthal Chemie 藥物劑型
JP2011511782A (ja) 2008-02-12 2011-04-14 アボット・ラボラトリーズ 長期放出性ヒドロコドンアセトアミノフェンならびにその関連方法および用途
ES2599031T3 (es) 2008-05-09 2017-01-31 Grünenthal GmbH Proceso para la preparación de una formulación de polvo intermedia y una forma de dosificación solida final utilizando un paso de congelación por pulverización
BR112012001466A2 (pt) 2009-07-22 2020-08-11 Grünenthal GmbH forma de dosagem resistente à falsificação para opioides sensíveis à oxidação, seu processo de fabricação, e embalagem
ES2534908T3 (es) 2009-07-22 2015-04-30 Grünenthal GmbH Forma de dosificación de liberación controlada extruida por fusión en caliente
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
US9884022B2 (en) * 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
BR112014002022A2 (pt) 2011-07-29 2017-02-21 Gruenenthal Gmbh comprimido resistente à violação proporcionando liberação de fármaco imediata
JP6063462B2 (ja) 2011-07-29 2017-01-18 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 即時薬剤放出を提供するタンパーレジスタント錠剤
BR112014019988A8 (pt) 2012-02-28 2017-07-11 Gruenenthal Gmbh Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico
LT2838512T (lt) 2012-04-18 2018-11-12 GrĆ¼nenthal GmbH Pažeidimui atspari ir dozės atpalaidavimo nuokrypiui atspari farmacinė vaisto forma
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
MX2015016254A (es) 2013-05-29 2016-04-20 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
HK1224189A1 (zh) 2013-11-26 2017-08-18 Grünenthal GmbH 通过低温研磨制备粉状药物组合物
WO2015173195A1 (en) 2014-05-12 2015-11-19 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
WO2016170097A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914131A (en) * 1994-07-07 1999-06-22 Alza Corporation Hydromorphone therapy
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
MXPA04010769A (es) * 2002-04-29 2005-07-05 Alza Corp Metodos y formas de dosificacion para suministro controlado de oxicodona.
CA2487786A1 (en) * 2002-05-31 2003-12-11 Alza Corporation Dosage forms and compositions for osmotic delivery of variable dosages of oxycodone

Also Published As

Publication number Publication date
AU2004285547A1 (en) 2005-05-12
JP2007509979A (ja) 2007-04-19
EP1677798A2 (en) 2006-07-12
CN1933837A (zh) 2007-03-21
RU2006118323A (ru) 2007-12-10
CA2546691A1 (en) 2005-05-12
WO2005041968A3 (en) 2006-06-22
KR20060108690A (ko) 2006-10-18
MA28215A1 (fr) 2006-10-02
WO2005041968A2 (en) 2005-05-12
IL175193A0 (en) 2008-04-13
NO20062398L (no) 2006-07-27
ZA200604310B (en) 2007-11-28
ECSP066534A (es) 2006-11-24

Similar Documents

Publication Publication Date Title
NO20062398L (no) Daglig, oral, kontrollert frigivnings oksycodon-doserings form
EP1670450B8 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2010009892A3 (en) Compositions for the treatment of pain and/or inflamation
TW200716628A (en) Novel compounds
GEP20247585B (en) Furoindazole derivatives
MX2010002733A (es) Terapia de intervalo para el tratamiento de tinnitus.
BR0309620A (pt) Métodos e formas de dosagem para liberação controlada de oxicodona
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
TW200517107A (en) Novel formulation
MY135829A (en) Analeptic and drug combinations
DE60027326D1 (de) Maca und geweih zur steigerung des testosteronspiegels
CY1118967T1 (el) Φαρμακευτικες συνθεσεις υψηλης δοσης βιοτινης
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
BR0314129A (pt) Formulações de liberação modificadas de oxcarbazepina e derivados destas
PT1638582E (pt) Uso de ácido hialurónico para a preparação de composições para o tratamento de aftas recorrentes da cavidade bucal
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
ATE410152T1 (de) Therapeutisches system mit amoxicillin und clavulansäure
CL2008002223A1 (es) Compuestos derivados de 9-desoxo-9a-metil-9a-aza-9a-homoeritromicina a 2'-o-sustituida; proceso de preparación; compuesto intermediario; composición farmacéutica; y su uso en el tratamiento y/o profilaxis de la malaria.
HRP20090513T1 (hr) S-mirtazapin, namijenjen liječenju napadaja vrućine
EA200501565A1 (ru) Предназначенная для перорального приёма лекарственная форма для антагонистов протонного насоса
MY140194A (en) Novel fusidic acid derivatives
TW200626140A (en) Preventing vertical endoparasite infections
NO20065791L (no) Asyklovir-formuleringer
SE0203817D0 (sv) New composition
BRPI0415428A (pt) formulações terapêuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.